Alessia Marrocu

Alessia Marrocu

Auto-generated profile, based on publicly available information

Alessia Marrocu

Centre for Psychedelic Research, Division of Psychiatry, Department of Brain Sciences, Faculty of Medicine, Imperial College London, London, UK

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 March 2024 in Journal of Psychopharmacology
Verified
Journal Article
Open access
AMAlessia Marrocu
Alessia Marrocu
HKHannes Kettner
Hannes Kettner
BWBrandon Weiss
Brandon Weiss
RZRichard Zeifman
Richard Zeifman
DEDavid Erritzoe
David Erritzoe
RCRobin L Carhart-Harris
Robin L Carhart-Harris
Background: Resurgent psychedelic research has largely supported the safety and efficacy of psychedelic therapy for the treatment of various psychiatric disorders. As psychedelic use and therapy increase in prevalence, so does the importance of understanding associated risks. Cases of prolonged negative psychological responses to psychedelic therapy seem to be rare; however, studies are limited by biases and small sample sizes. The current analytical approach was motivated by the question of whether rare but significant adverse effects have been under-sampled in psychedelic research studies. Methods: A “bottom margin analysis” approach was taken to focus on negative responders to psychedelic use in a pool of naturalistic, observational prospective studies ( N = 807). We define “negative response” by a clinically meaningful decline in a generic index of mental health, that is, one standard error from the mean decrease in psychological well-being 4 weeks post-psychedelic use (vs pre-use baseline). We then assessed whether a history of diagnosed mental illness can predict negative responses. Results: We find that 16% of the cohort falls into the “negative responder” subset. Parsing the sample by self-reported history of psychiatric diagnoses, results revealed a disproportionate prevalence of negative responses among those reporting a prior personality disorder diagnosis (31%). One multivariate regression model indicated a greater than four-fold elevated risk of adverse psychological responses to psychedelics in the personality disorder subsample ( b = 1.425, p < 0.05). Conclusion: We infer that the presence of a personality disorder may represent an elevated risk for psychedelic use and hypothesize that the importance of psychological support and good therapeutic alliance may be increased in this population.

1 March 2021 in Brain, Behavior, and Immunity
Verified
Journal Article
Closed access
JGJuliette Giacobbe
Juliette Giacobbe
AMAlessia Marrocu
Alessia Marrocu
MBMaria Grazia Di Benedetto
Maria Grazia Di Benedetto
CPCarmine M. Pariante
Carmine M. Pariante
ABAlessandra Borsini
Alessandra Borsini

17 October 2023 in PsyArXiv
Verified
Preprint
Open access
AMAlessia Marrocu
Alessia Marrocu
HKHannes Kettner
Hannes Kettner
BWBrandon Weiss
Brandon Weiss
RZRichard Zeifman
Richard Zeifman
DEDavid Erritzoe
David Erritzoe
RCRobin Carhart-Harris
Robin Carhart-Harris
Background: Resurgent psychedelic research has largely supported the safety and efficacy of psychedelic therapy for the treatment of various psychiatric disorders. As psychedelic use and therapy increases in prevalence, so does the importance of understanding associated risks. Cases of prolonged negative psychological responses to psychedelic therapy seem rare; however, studies are limited by biases and small sample sizes. The current analytical approach was motivated by the question of whether rare but significant adverse effects have been under-sampled in psychedelic research studies. Methods: A ‘bottom margin analysis’ approach was taken to focus on negative responders to psychedelic use in a pool of naturalistic, observational prospective studies (N=807). We define ‘negative response’ by a clinically meaningful decline in a generic index of mental health, i.e., a one standard error from the mean decrease in psychological well-being 4 weeks post psychedelic use (vs pre-use baseline). We then assessed whether a history of diagnosed mental illness can predict negative responses. Results: We find that 16% of the cohort fall into the ‘negative responder’ subset. Parsing the sample by self-reported history of psychiatric diagnoses, , results revealed a disproportionate prevalence of negative responses among those reporting a prior personality disorder diagnosis (31%). One multivariate regression model indicated a greater than four-fold elevated risk of adverse psychological responses to psychedelics in the personality-disorder sub-sample (b = 1.425, p < 0.05). Conclusion: We infer that the presence of a personality disorder may represent an elevated risk for psychedelic use, and hypothesize that the importance of psychological support and good therapeutic alliance may be increased in this population.